Growth Metrics

Pfizer (PFE) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Pfizer (PFE) over the last 17 years, with Q2 2025 value amounting to $25.0 million.

  • Pfizer's Income towards Parent Company rose 4705.88% to $25.0 million in Q2 2025 from the same period last year, while for Sep 2025 it was $25.0 million, marking a year-over-year increase of 21363.64%. This contributed to the annual value of $11.0 million for FY2024, which is 17333.33% up from last year.
  • As of Q2 2025, Pfizer's Income towards Parent Company stood at $25.0 million, which was up 4705.88% from -$8.0 million recorded in Q3 2024.
  • Pfizer's Income towards Parent Company's 5-year high stood at $34.0 million during Q3 2022, with a 5-year trough of -$236.0 million in Q3 2021.
  • Over the past 5 years, Pfizer's median Income towards Parent Company value was -$3.5 million (recorded in 2023), while the average stood at -$16.4 million.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first plummeted by 100000.0% in 2022, then surged by 95000.0% in 2024.
  • Quarter analysis of 5 years shows Pfizer's Income towards Parent Company stood at -$13.0 million in 2021, then plummeted by 61.54% to -$21.0 million in 2022, then fell by 23.81% to -$26.0 million in 2023, then surged by 69.23% to -$8.0 million in 2024, then surged by 412.5% to $25.0 million in 2025.
  • Its Income towards Parent Company stands at $25.0 million for Q2 2025, versus -$8.0 million for Q3 2024 and $17.0 million for Q2 2024.